Novartis Gene Therapies Revenue and Competitors

Bannockburn, CO USA

Location

N/A

Total Funding

Industry

Estimated Revenue & Valuation

  • Novartis Gene Therapies's estimated annual revenue is currently $52.4B per year.(i)
  • Novartis Gene Therapies's estimated revenue per employee is $64,919,455
  • Novartis Gene Therapies's current valuation is $202.6B. (January 2022)

Employee Data

  • Novartis Gene Therapies has 807 Employees.(i)
  • Novartis Gene Therapies grew their employee count by -16% last year.

Novartis Gene Therapies's People

NameTitleEmail/Phone
1
Senior Fellow/Team Coordinator/Application Owner eLN@TRD/Network Leader Lab AutomationReveal Email/Phone
2
Digital Product Owner (Tech)Reveal Email/Phone
3
Executive Director, CEO & Executive CommunicationsReveal Email/Phone
4
Process mining ownerReveal Email/Phone
5
Product Owner, data42Reveal Email/Phone
6
Global Expense Process OwnerReveal Email/Phone
7
System Governance Manager & System Owner TRD SAPReveal Email/Phone
8
LDC Product Cost Controlling Manager & Global Process Owner Product Cost SimulationReveal Email/Phone
9
Omnichannel Product OwnerReveal Email/Phone
10
Global ESG Reporting Process OwnerReveal Email/Phone

What Is Novartis Gene Therapies?

At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

keywords:N/A

N/A

Total Funding

807

Number of Employees

$52.4B

Revenue (est)

-16%

Employee Growth %

$202.6B

Valuation

N/A

Accelerator

Novartis Gene Therapies News

2022-04-19 - Satellite Bio launches with new approach to bioengineering ...

Backed by $110 million in venture funding, Satellite is led by Dave Lennon, formerly head of Novartis Gene Therapies.

2022-04-06 - FDA clears second Novartis plant for gene therapy ...

The Food and Drug Administration has cleared a Novartis manufacturing plant in North Carolina to produce commercial-grade gene therapies,...

2022-04-06 - Novartis expands Zolgensma manufacturing capacity with ...

Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge...

2021-11-16 - Covid-19 roundup: Pfiz­er li­cens­es its pill to the Med­i­cines Patent Pool; NYC joins states in au­tho­riz­ing boost­ers for all adults ahead of FDA

Novartis bet large on The Medicines Company’s RNAi heart drug inclisiran, expecting to shake up that segment of the market with a swift US approval. But after getting stiff-armed by the FDA last year, the pharma giant’s now releasing more post-hoc data in the hopes of finally running it past the ...

2021-10-27 - Feds probe Novartis over Entresto marketing and compensation to doctors

In what might become a new scandal for Novartis, federal investigators recently demanded information from the drug maker (NVS) about the pricing and marketing of one of its biggest-selling drugs, and the focus of the probe includes compensation paid to physicians. Last month, the U.S. Departmen ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A228127%N/A
#2
$3320M57608%N/A